Holen Sie sich die Stockscreener-App
812.31
0.91%
-7.0856
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$819.40
Offen:
$822.09
24-Stunden-Volumen:
755.77K
Relative Volume:
0.17
Marktkapitalisierung:
$768.59B
Einnahmen:
$53.26B
Nettoeinkommen (Verlust:
$13.80B
KGV:
53.86
EPS:
15.0808
Netto-Cashflow:
$-50.20M
1W Leistung:
-3.75%
1M Leistung:
+7.49%
6M Leistung:
+7.64%
1J Leistung:
-12.65%
1-Tages-Spanne:
$806.00
$822.09
1-Wochen-Bereich:
$806.00
$864.35
52-Wochen-Spanne:
$623.78
$935.62
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Vergleichen Sie LLY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
812.08 | 747.19B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
187.83 | 459.32B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
228.83 | 407.19B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
129.95 | 251.72B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
84.64 | 214.78B | 63.43B | 16.42B | 14.72B | 6.4861 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly doubles down on Mounjaro despite rising competition in Brazil - Valor International
The Zacks Analyst Blog Highlights Apple, Eli Lilly and Visa - Yahoo
FDA Approves Alzheimer’s Test Developed By Roche In Collaboration With Eli Lilly - Stocktwits
Erste Group upgrades Eli Lilly stock rating to Buy after strong H1 results - Investing.com Canada
Top Stock Reports for Apple, Eli Lilly & Visa - Nasdaq
Eli Lilly and Company Strengthens Presence Among S&P 500 Companies - Kalkine Media
Eli Lilly: The Rally Has More Room To Run (Rating Upgrade) (NYSE:LLY) - Seeking Alpha
Down 44%, Should You Buy the Dip on Viking Therapeutics? - The Motley Fool
Lilly Wants To Know: What Does Chronic Illness Really Look Like? 10/13/2025 - MediaPost
Precision Trading with Eli Lilly And Company (LLY) Risk Zones - news.stocktradersdaily.com
Eli Lilly Omvoh Demonstrates Sustained Long-Term Benefits in Ulcerative Colitis Up to Four Years - Yahoo Finance
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Oct 2025) - 24/7 Wall St.
Eli Lilly Opens R&D Incubator for Life Sciences Startups - San Diego Business Journal
Aspen wins approval to market Lilly's Mounjaro for weight loss in South Africa - Reuters
Should Omvoh’s Clinical Success and Earnings Optimism Prompt Action from Eli Lilly (LLY) Investors? - simplywall.st
Should Omvoh’s Clinical Results and Innovation Drive a Rethink of Eli Lilly’s (LLY) Specialty Focus? - Yahoo Finance
The Goldman Sachs Group Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price - MarketBeat
Insider Sales Surge: Block, Eli Lilly, Strategy, P&G, Dell - TipRanks
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Val T. Hoyle - MarketBeat
Should Investors Buy Eli Lilly Stock? - The Globe and Mail
Meet this year’s Women in Biopharma; Peter Marks goes to Eli Lilly; Bob Langer startup launches; and more - Endpoints News
Gunderson Capital Management Inc. Increases Position in Eli Lilly and Company $LLY - MarketBeat
Seeking Safe Havens: Why Pfizer and Eli Lilly Are Top Market Picks Now? - NAI500
Major Shareholder Sells Millions in Eli Lilly Stock! - TipRanks
Eli Lilly (LLY): Revisiting Valuation After Recent Share Price Gains - simplywall.st
Lilly Endowment sells Eli Lilly shares worth $9.04 million - Investing.com
Eli Lilly and Co(LLY.US) 10% Shareholder Sells US$9.04 Million in Common Stock - 富途牛牛
Lilly Endowment unloads about $600 million in Eli Lilly stock during early October - Sherwood News
Eli Lilly’s New Study on Weight Reduction Drugs: A Potential Market Game-Changer? - TipRanks
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly - Reuters
Next Medicine Deal After Pfizer? Analysts, Shares Point to AstraZeneca, Eli Lilly - Money US News.com
WHO Arm Seeks Talks with Novo Nordisk, Eli Lilly on Expanding Access to Weight-loss Drugs - MarketScreener
Shape’s former CSO picks up tech role at Moderna; Lilly reels in Peter Marks - Endpoints News
2 Pharmaceutical Stocks That Look Like No-Brainer Buys Right Now - The Globe and Mail
Verde Servicos Internacionais S.A. Purchases New Position in Eli Lilly and Company $LLY - MarketBeat
Baxter Bros Inc. Lowers Stock Position in Eli Lilly and Company $LLY - MarketBeat
Major Shareholder Cashes Out Millions in Eli Lilly Stock! - TipRanks
LILLY ENDOWMENT INC Reduces Stake in Eli Lilly and Co - GuruFocus
Eli Lilly (LLY) Gains As Market Dips: What You Should Know - Yahoo Finance
Lilly Endowment sells Eli Lilly & Co (LLY) shares for $86.2m - Investing.com Canada
A Major Eli Lilly Shareholder Has Sold Stock Nearly Every Day in October. Here’s Who It Is. - MSN
Eli Lilly Completes Phase 1 Study for Bimagrumab and Tirzepatide Amidst Strategic Pipeline Revisions - FinancialContent
Lobbying Update: $10,000 of ELI LILLY & COMPANY lobbying was just disclosed - Quiver Quantitative
Eli Lilly Completes Phase 1 Study on Bimagrumab and Tirzepatide: Market Implications - TipRanks
US-based Eli Lilly to invest $1 billion in India - The Indian EYE
AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025? - Nasdaq
Eli Lilly and Company ($LLY) Stock: Appoints Former FDA Biologics Head Peter Marks as Senior VP of Molecule Discovery - CoinCentral
Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market - Yahoo Finance
Cantor Fitzgerald Adjusts PT on Eli Lilly and Co. to $925 From $825, Maintains Overweight Rating - MarketScreener
Notis McConarty Edward Acquires 1,424 Shares of Eli Lilly and Company $LLY - MarketBeat
Capital Management Associates Inc Cuts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.61%
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):